-
Innovation Ranking
NewInnovation Ranking – Aclaris Therapeutics Inc
Aclaris Therapeutics Inc (Aclaris Therapeutics) is bio-pharmaceutical company focused on identifying, developing and commercializing small molecule therapies for immuno-inflammatory conditions. Its lead product, ESKATA is a proprietary formulation of high-concentration hydrogen peroxide topical solution prescribed for the treatment of raised seborrheic keratosis (SK). The company's pipeline products include A-101, ATI-1777-oral JAK 1/3 inhibitor, ATI-501, ATI-450-oral MK2 pathway inhibitor, soft JAK inhibitor, ITK oral anti-IL17 and ITK topical anti-IL17.Aclaris Therapeutics’ pipeline products are used for the treatment of common warts, alopecia...
-
Company Insights
Innovation and Patenting activity of Aclaris Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Aclaris Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Favezelimab
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Favezelimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lepzacitinib in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lepzacitinib in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lepzacitinib in Atopic Dermatitis (Atopic Eczema) Drug Details: ATI-1777 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Psoriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATI-2138 in Psoriasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Psoriasis Drug Details: ATI-2138 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATI-2138 in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Ulcerative Colitis Drug Details: ATI-2138 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ipilimumab in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ipilimumab in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ipilimumab in Soft Tissue Sarcoma Drug Details: Ipilimumab (Yervoy, Winglore)...
-
Product Insights
Dermatosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Dermatosis - Drugs In Development, 2023’, provides an overview of the Dermatosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dermatosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Human Papillomavirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Human Papillomavirus Infections - Drugs In Development, 2023’, provides an overview of the Human Papillomavirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteoporosis - Drugs In Development, 2023’, provides an overview of the Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...